Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -5.95 is 1118% below its 5-year average of 0.58, near the low end of its 5-year range (-5.95–7.46).
As of the fiscal period ended Tuesday, June 30, 2026. 354.94% below its 12-month average of 2.33.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -5.95.
DEBT TO EQUITY RATIO
-5.95
DEBT TO EQUITY RATIO AVG TTM
2.33
DEBT TO EQUITY RATIO AVG 3Y
1.22
DEBT TO EQUITY RATIO AVG 5Y
0.58
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-354.94%
CURRENT VS 3Y AVG
-587.97%
CURRENT VS 5Y AVG
-1118.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-5506.43%
vs the sector median at left
Senti Biosciences, Inc.
Market Cap
$10.58M
Debt to Equity Ratio
-5.95
TTM Avg
2.33
3Y Avg
1.22
5Y Avg
0.58
Market Cap
$10.51M
Debt to Equity Ratio
0.09
TTM Avg
0.06
3Y Avg
1.84
5Y Avg
2.48
Market Cap
$10.41M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.02
Market Cap
$10.38M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$11.00M
Debt to Equity Ratio
0.00
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.03
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Senti Biosciences, Inc. (SNTI) | $10.58M | -5.95 | 2.33 | 1.22 | 0.58 |
| Pluri Inc. (PLUR)vs › | $10.59M | N/A | 155.35 | 78.02 | 52.02 |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.51M | 0.09 | 0.06 | 1.84 | 2.48 |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.41M | 0.02 | 0.01 | 0.01 | 0.02 |
| Polyrizon Ltd. (PLRZ)vs › | $10.58M | 0.00 | 0.00 | 0.88 | 0.58 |
| Satellos Bioscience Inc. (MSLE)vs › | $10.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| Lifeward Ltd. (LFWD)vs › | $10.26M | 0.91 | 0.29 | 0.15 | 0.12 |
| Caring Brands, Inc. (CABR)vs › | $11.00M | 0.00 | 0.03 | 0.03 | 0.03 |
| BioVie Inc. (BIVI)vs › | $11.01M | 0.03 | 0.03 | 0.35 | 0.79 |
| MetaVia Inc. (MTVA)vs › | $9.62M | 0.03 | 0.03 | 0.02 | 0.01 |
Debt/Equity
-5.95
Current Ratio
0.83
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -5.95 |
| 2026-03-31 | 7.46 |
| 2025-12-31 | 5.17 |
| 2025-09-30 | 3.71 |
| 2025-06-30 | 1.27 |
| 2025-03-31 | 0.86 |
| 2024-12-31 | 1.31 |
| 2024-09-30 | 2.17 |
| 2024-06-30 | 0.81 |
| 2024-03-31 | 0.65 |
| 2023-12-31 | 0.56 |
| 2023-09-30 | 0.45 |
| 2023-06-30 | 0.39 |
| 2023-03-31 | 0.34 |
| 2022-12-31 | 0.29 |
| 2022-09-30 | 0.24 |
| 2022-06-30 | 0.20 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.38 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | -0.24 |
